High‑risk pathological subtype associated FAM83A‑AS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR‑202‑3p/HK2 axis

Xiong,Xinkui; Zhang,Lei; Zang,Bao; Xu,Dafu; Chen,Chen; Dong,Gaochao; Xia,Wenjie; Wu,Yanhu

doi:10.3892/or.2023.8532

High‑risk pathological subtype associated FAM83A‑AS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR‑202‑3p/HK2 axis

Authors:
- Xinkui Xiong
- Lei Zhang
- Bao Zang
- Dafu Xu
- Chen Chen
- Gaochao Dong
- Wenjie Xia
- Yanhu Wu
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaiyin, Huaian, Jiangsu 223001, P.R. China, Department of Medical Oncology, Xuzhou Central Hospital, Quanshan, Xuzhou 221000, P.R. China, Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210000, P.R. China, Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China
Published online on: March 22, 2023 https://doi.org/10.3892/or.2023.8532
Article Number: 95
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

According to the diverse cellular morphology, lung adenocarcinoma (LUAD) was classified into five pathological subtypes, referred to as follows: High‑risk group (micropapillary and solid), intermediate‑risk group (acinar and papillary) and low‑risk group (epidic). Nevertheless, little is known about the biological function of long non‑coding RNA (lncRNA) in the molecular determination of LUAD histologic patterns. Screening the transcriptional expression data from TCGA‑LUAD, the differentially expressed lncRNA across the divergent pathological subtypes were explored. Pan‑cancer analysis revealed the characteristic of FAM83A‑AS1, which was also confirmed in the LUAD tissues. The function of FAM83A‑AS1 was uncovered through the in vitro assays. RNA immunoprecipitation and dual‑luciferase reporter assays were performed to explore the molecular mechanisms of FAM83A‑AS1. In the present study, it was identified that the expression of FAM83A‑AS1 was increased from the low‑risk group to the high, which was associated with a poorer prognosis and higher risk of recurrence. Pan‑cancer analysis revealed that FAM83A‑AS1 was positively correlated with high tumor mutational burden. Additionally, FAM83A‑AS1 promoted cell migration, invasion and growth of LUAD cancer cells. Mechanistically, FAM83A‑AS1 sponged miR‑202‑3p to regulate the expression of hexokinase II (HK2) in post‑transcription, which facilitated the malignancy and glycolysis. The present study uncovered the biological roles of FAM83A‑AS1/miR‑202‑3p/HK2 axis in regulating malignancy and glycolysis of LUAD, which provided novel avenues to addressing the determination of histologic patterns.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	He D, Wang D, Lu P, Yang N, Xue Z, Zhu X, Zhang P and Fan G: Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene. 40:355–368. 2021. View Article : Google Scholar : PubMed/NCBI
3	Dong ZY, Zhang C, Li YF, Su J, Xie Z, Liu SY, Yan LX, Chen ZH, Yang XN, Lin JT, et al: Genetic and immune profiles of solid predominant lung adenocarcinoma reveal potential immunotherapeutic strategies. J Thorac Oncol. 13:85–96. 2018. View Article : Google Scholar : PubMed/NCBI
4	Schneider F and Dacic S: Histopathologic and molecular approach to staging of multiple lung nodules. Transl Lung Cancer Res. 6:540–549. 2017. View Article : Google Scholar : PubMed/NCBI
5	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
6	Yousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Reza Aref A, Momeny M and Alahari SK: Long noncoding RNAs and exosomal lncRNAs: Classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 39:953–974. 2020. View Article : Google Scholar : PubMed/NCBI
7	Li SY, Zhu Y, Li RN, Huang JH, You K, Yuan YF and Zhuang SM: LncRNA Lnc-APUE is repressed by HNF4α and promotes G1/S phase transition and tumor growth by regulating MiR-20b/E2F1 axis. Adv Sci (Weinh). 8:20030942021. View Article : Google Scholar : PubMed/NCBI
8	Parasramka MA, Maji S, Matsuda A, Yan IK and Patel T: Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 161:67–78. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chen HY, Chan SJ, Liu X, Wei AC, Jian RI, Huang KW, Lang YD, Shih JH, Liao CC, Luan CL, et al: Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression. J Hematol Oncol. 15:852022. View Article : Google Scholar : PubMed/NCBI
10	Ma F, Liu X, Zhou S, Li W, Liu C, Chadwick M and Qian C: Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. Cancer Lett. 450:63–75. 2019. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Venkatesh J, Wasson MD, Brown JM, Fernando W and Marcato P: LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett. 509:81–88. 2021. View Article : Google Scholar : PubMed/NCBI
13	Huang H, Yang C, Zhang Q, Zhuo T, Li X, Li N, Zhu L, Luo C, Gan J and Wu Y: Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression. Bioengineered. 13:4964–4977. 2022. View Article : Google Scholar : PubMed/NCBI
14	Jiang J, Bi Y, Liu XP, Yu D, Yan X, Yao J, Liu T and Li S: To construct a ceRNA regulatory network as prognostic biomarkers for bladder cancer. J Cell Mol Med. 24:5375–5386. 2020. View Article : Google Scholar : PubMed/NCBI
15	Su L, Li R, Zhang Z, Liu J, Du J and Wei H: Identification of altered exosomal microRNAs and mRNAs in Alzheimer's disease. Ageing Res Rev. 73:1014972022. View Article : Google Scholar : PubMed/NCBI
16	Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F, Liu C, Zhang G, Wang Z, Wang R, et al: B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 10:3082019. View Article : Google Scholar : PubMed/NCBI
17	Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, Nguyen B, Schultz N, Connolly JG, Brandt WS, et al: The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol. 15:1844–1856. 2020. View Article : Google Scholar : PubMed/NCBI
18	Shi Q, Shao K, Jia H, Cao B, Li W, Dong S, Liu J, Wu K, Liu M, Liu F, et al: Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast. Nat Commun. 13:1112022. View Article : Google Scholar : PubMed/NCBI
19	Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, Peters S, Krueger T, Gfeller D, Riggi N, et al: Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. Cancer Discov. 11:1490–1507. 2021. View Article : Google Scholar : PubMed/NCBI
20	Sato R, Imamura K, Semba T, Tomita Y, Saeki S, Ikeda K, Komohara Y, Suzuki M, Sakagami T, Saya H and Arima Y: TGFβ signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 81:4751–4765. 2021. View Article : Google Scholar : PubMed/NCBI
21	Zhang S, Xu Y, Zhao P, Bao H, Wang X, Liu R, Xu R, Xiang J, Jiang H, Yan J, et al: Integrated analysis of genomic and immunological features in lung adenocarcinoma with micropapillary component. Front Oncol. 11:6521932021. View Article : Google Scholar : PubMed/NCBI
22	Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, et al: The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 12:70812021. View Article : Google Scholar : PubMed/NCBI
23	Nguyen TT, Lee HS, Burt BM, Wu J, Zhang J, Amos CI and Cheng C: A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Med. 14:52022. View Article : Google Scholar : PubMed/NCBI
24	Chen Z, Hu Z, Sui Q, Huang Y, Zhao M, Li M, Liang J, Lu T, Zhan C, Lin Z, et al: LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/glycolysis axis in lung adenocarcinoma. Int J Biol Sci. 18:522–535. 2022. View Article : Google Scholar : PubMed/NCBI
25	Jia J, Li H, Chu J, Sheng J, Wang C, Jia Z, Meng W, Yin H, Wan J and He F: LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis. J Cancer. 12:1200–1211. 2021. View Article : Google Scholar : PubMed/NCBI
26	He J and Yu J: Long noncoding RNA FAM83A-AS1 facilitates hepatocellular carcinoma progression by binding with NOP58 to enhance the mRNA stability of FAM83A. Biosci Rep. 39:BSR201925502019. View Article : Google Scholar : PubMed/NCBI
27	Wang W, Zhao Z, Xu C, Li C, Ding C, Chen J, Chen T and Zhao J: LncRNA FAM83A-AS1 promotes lung adenocarcinoma progression by enhancing the pre-mRNA stability of FAM83A. Thorac Cancer. 12:1495–1502. 2021. View Article : Google Scholar : PubMed/NCBI
28	Xiao G, Wang P, Zheng X, Liu D and Sun X: FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14. Cell Cycle. 18:2972–2985. 2019. View Article : Google Scholar : PubMed/NCBI
29	Lunt SY and Vander Heiden MG: Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
30	Zhou L, Li M, Yu X, Gao F and Li W: Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int J Biol Sci. 15:826–837. 2019. View Article : Google Scholar : PubMed/NCBI
31	Tantai J, Pan X, Chen Y, Shen Y and Ji C: TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells. Cell Death Dis. 13:2852022. View Article : Google Scholar : PubMed/NCBI
32	Li X, Li Y, Bai S, Zhang J, Liu Z and Yang J: NR2F1-AS1/miR-140/HK2 axis regulates hypoxia-induced glycolysis and migration in hepatocellular carcinoma. Cancer Manag Res. 13:427–437. 2021. View Article : Google Scholar : PubMed/NCBI
33	Chen J, Yu Y, Li H, Hu Q, Chen X, He Y, Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Mol Cancer. 18:332019. View Article : Google Scholar : PubMed/NCBI
34	Yu T, Li G, Wang C, Gong G, Wang L, Li C, Chen Y and Wang X: MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis. RNA Biol. 18:2513–2530. 2021. View Article : Google Scholar : PubMed/NCBI